Introduction:
Fondaparinux is a factor Xa inhibitor used for venous thromboembolism prevention and treatment [1]. It has a low affinity for platelet factor 4, making it an alternative agent to unfractionated heparin (UFH) and low-molecular weight heparin (LMWH) and a plausible consideration for patients with a history of HIT with decreased platelets and hypercoagulable state [2,3]. The use of fondaparinux as a bridging therapy in patients with mitral mechanical heart valve replacement and severe thrombocytopenia due to chemotherapy has never been discussed before in the literature.
We report a case of a patient with a mechanical mitral valve replacement and thrombocytopenia chemotherapy induced with a successful bridging with fondaparinux. While there is currently no literature for the use of fondaparinux in patients with mechanical heart valves.